Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
ChemMedChem
2009 Mar 01;43:406-14. doi: 10.1002/cmdc.200800292.
Show Gene links
Show Anatomy links
Structurally minimized mu-conotoxin analogues as sodium channel blockers: implications for designing conopeptide-based therapeutics.
Han TS
,
Zhang MM
,
Walewska A
,
Gruszczynski P
,
Robertson CR
,
Cheatham TE
,
Yoshikami D
,
Olivera BM
,
Bulaj G
.
???displayArticle.abstract???
Disulfide bridges that stabilize the native conformation of conotoxins pose a challenge in the synthesis of smaller conotoxin analogues. Herein we describe the synthesis of a minimized analogue of the analgesic mu-conotoxin KIIIA that blocks two sodium channel subtypes, the neuronal Na(V)1.2 and skeletal muscle Na(V)1.4. Three disulfide-deficient analogues of KIIIA were initially synthesized in which the native disulfide bridge formed between either C1-C9, C2-C15, or C4-C16 was removed. Deletion of the first bridge only slightly affected the peptide's bioactivity. To further minimize this analogue, the N-terminal residue was removed and two nonessential serine residues were replaced by a single 5-amino-3-oxapentanoic acid residue. The resulting "polytide" analogue retained the ability to block sodium channels and to produce analgesia. Until now, the peptidomimetic approach applied to conotoxins has progressed only modestly at best; thus, the disulfide-deficient analogues containing backbone spacers provide an alternative advance toward the development of conopeptide-based therapeutics.
Amir,
The role of sodium channels in chronic inflammatory and neuropathic pain.
2006, Pubmed
Amir,
The role of sodium channels in chronic inflammatory and neuropathic pain.
2006,
Pubmed
Armishaw,
Conotoxins as research tools and drug leads.
2005,
Pubmed
Baell,
Design and synthesis of type-III mimetics of ShK toxin.
2002,
Pubmed
Baell,
Synthesis and biological evaluation of nonpeptide mimetics of omega-conotoxin GVIA.
2004,
Pubmed
Baell,
Design and synthesis of type-III mimetics of omega-conotoxin GVIA.
2001,
Pubmed
Bulaj,
Synthetic muO-conotoxin MrVIB blocks TTX-resistant sodium channel NaV1.8 and has a long-lasting analgesic activity.
2006,
Pubmed
Case,
The Amber biomolecular simulation programs.
2005,
Pubmed
Chen,
Determination of the helix and beta form of proteins in aqueous solution by circular dichroism.
1974,
Pubmed
Cruz,
mu-conotoxin GIIIA, a peptide ligand for muscle sodium channels: chemical synthesis, radiolabeling, and receptor characterization.
1989,
Pubmed
Cruz,
Conus geographus toxins that discriminate between neuronal and muscle sodium channels.
1985,
Pubmed
Cummins,
Voltage-gated sodium channel blockers for the treatment of neuropathic pain.
2007,
Pubmed
Cummins,
The roles of sodium channels in nociception: Implications for mechanisms of pain.
2007,
Pubmed
Davis,
Synthetic non-peptide mimetics of alpha-helices.
2007,
Pubmed
Ekberg,
muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits.
2006,
Pubmed
,
Xenbase
Fajloun,
Synthesis, 1H NMR structure, and activity of a three-disulfide-bridged maurotoxin analog designed to restore the consensus motif of scorpion toxins.
2000,
Pubmed
Flinn,
Role of disulfide bridges in the folding, structure and biological activity of omega-conotoxin GVIA.
1999,
Pubmed
French,
Sodium channel toxins--receptor targeting and therapeutic potential.
2004,
Pubmed
Green,
Conotoxins containing nonnatural backbone spacers: cladistic-based design, chemical synthesis, and improved analgesic activity.
2007,
Pubmed
Han,
Conus venoms - a rich source of peptide-based therapeutics.
2008,
Pubmed
Hornak,
Comparison of multiple Amber force fields and development of improved protein backbone parameters.
2006,
Pubmed
Jarvis,
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
2007,
Pubmed
Jin,
Molecular engineering of conotoxins: the importance of loop size to alpha-conotoxin structure and function.
2008,
Pubmed
,
Xenbase
Jones,
Conotoxins - new vistas for peptide therapeutics.
2000,
Pubmed
Kaerner,
Stability and structure-forming properties of the two disulfide bonds of alpha-conotoxin GI.
1999,
Pubmed
Keizer,
Structural basis for tetrodotoxin-resistant sodium channel binding by mu-conotoxin SmIIIA.
2003,
Pubmed
Lamthanh,
Minimal conformation of the alpha-conotoxin ImI for the alpha7 neuronal nicotinic acetylcholine receptor recognition: correlated CD, NMR and binding studies.
1999,
Pubmed
Lancelin,
Tertiary structure of conotoxin GIIIA in aqueous solution.
1991,
Pubmed
Lanigan,
Designed peptide analogues of the potassium channel blocker ShK toxin.
2001,
Pubmed
,
Xenbase
Lewis,
Isolation and structure-activity of mu-conotoxin TIIIA, a potent inhibitor of tetrodotoxin-sensitive voltage-gated sodium channels.
2007,
Pubmed
,
Xenbase
Livett,
Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor.
2006,
Pubmed
Livett,
Drugs from the sea: conopeptides as potential therapeutics.
2004,
Pubmed
Miljanich,
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
2004,
Pubmed
Mills,
An alpha-helical peptidomimetic inhibitor of the HIV-1 Rev-RRE interaction.
2006,
Pubmed
Nielsen,
Solution structure of mu-conotoxin PIIIA, a preferential inhibitor of persistent tetrodotoxin-sensitive sodium channels.
2002,
Pubmed
Norton,
Conotoxins down under.
2006,
Pubmed
Olivera,
Conus peptides: biodiversity-based discovery and exogenomics.
2006,
Pubmed
Onufriev,
Exploring protein native states and large-scale conformational changes with a modified generalized born model.
2004,
Pubmed
Pallaghy,
The cyclic contryphan motif CPxXPXC, a robust scaffold potentially useful as an omega-conotoxin mimic.
2000,
Pubmed
Pennington,
Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin.
1999,
Pubmed
,
Xenbase
Price-Carter,
Initial disulfide formation steps in the folding of an omega-conotoxin.
2002,
Pubmed
Price-Carter,
Roles of individual disulfide bonds in the stability and folding of an omega-conotoxin.
1998,
Pubmed
Priest,
Blocking sodium channels to treat neuropathic pain.
2007,
Pubmed
Rizzuti,
Evidence of reduced flexibility in disulfide bridge-depleted azurin: a molecular dynamics simulation study.
2001,
Pubmed
Schmalhofer,
ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors.
2008,
Pubmed
Schroeder,
Neuronally micro-conotoxins from Conus striatus utilize an alpha-helical motif to target mammalian sodium channels.
2008,
Pubmed
,
Xenbase
Wakamatsu,
Structure-activity relationships of mu-conotoxin GIIIA: structure determination of active and inactive sodium channel blocker peptides by NMR and simulated annealing calculations.
1992,
Pubmed
Wallace,
Calcium and sodium channel antagonists for the treatment of pain.
2000,
Pubmed
Yao,
Structure, dynamics, and selectivity of the sodium channel blocker mu-conotoxin SIIIA.
2008,
Pubmed
,
Xenbase
Zhang,
Structural and functional diversities among mu-conotoxins targeting TTX-resistant sodium channels.
2006,
Pubmed
Zhang,
Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels.
2007,
Pubmed
,
Xenbase